

## Technology Advisory Committee C Interests Register

### Topic Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [ID4045]

Publication Date: 6 March 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	Committee Member	Financial	Mr Chambers has participated in an advisory panel for comparator company Pfizer in an unrelated disease area (prostate cancer).	19/09/2023	It was agreed that Mr Chambers' declaration would not prevent him from participating in discussions on this appraisal.
Dr Kate Ren	Committee Member	Financial	Dr Ren has provided statistical methodology consultancy service for comparator company Pfizer (tofacitinib for patients with moderate-to-severe ulcerative colitis).	19/09/2023	It was agreed that Dr Ren's declaration would not prevent her from participating in discussions on this appraisal.
Dr Steven Lloyd	Committee Member	Financial	Dr Lloyd has done paid work by AbbVie on immunology referral pathways.	20/09/2023	It was agreed that Dr Lloyd's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Elizabeth Thurgar	Committee member	Financial	Ms Thurgar has worked with comparator company Kite on a project relating to Mantle Cell Lymphoma.	22/11/2023	It was agreed that Ms Thurgar's declaration would not prevent her from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee Member	Financial	Dr Nicholas has attended paid advisory boards with Roche in an unrelated disease area - multiple sclerosis.	22/11/2023	It was agreed that Dr Nicholas' declaration would not prevent him from participating in discussions on this appraisal.
Professor David Lewis	Clinical expert	Financial	<p>He has received payment to attend an Abbvie/Genmab hosted clinical advisory board meeting in February 2023 for which he was remunerated.</p> <p>Professor Lewis was part of a speaker bureau for AbbVie in June 2023.</p> <p>Professor Lewis also reviewed health economic data which in part contributed to the company submission which he was remunerated for.</p>	<p>07/03/2023</p> <p>04/10/2023</p> <p>12/12/2023</p>	It was agreed that Professor Lewis' declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Wendy Osborne	Clinical expert	Financial	Dr Osborne has received speaker fees, advisory fees and travel support from AbbVie, Roche, Pfizer, Servier, Kite Gilead, Incyte and BMS Celgene.	27/04/2023	It was agreed that Dr Osborne's declaration would not prevent her from providing expert advice to the committee.